Analysts Set Pfizer Inc. (NYSE:PFE) Price Target at $36.33

Pfizer Inc. (NYSE:PFE) has been given a consensus recommendation of “Hold” by the sixteen research firms that are currently covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $36.33.

A number of brokerages have recently issued reports on PFE. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd.

Institutional Investors Weigh In On Pfizer

Large investors have recently made changes to their positions in the stock. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the third quarter worth $30,000. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the fourth quarter worth $32,000. Trivant Custom Portfolio Group LLC increased its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the third quarter worth $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $25.61 on Friday. Pfizer has a 1 year low of $25.20 and a 1 year high of $40.37. The firm’s 50 day moving average is $26.88 and its 200-day moving average is $28.26. The firm has a market capitalization of $145.02 billion, a price-to-earnings ratio of 71.14, a PEG ratio of 1.14 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the business earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. Sell-side analysts forecast that Pfizer will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.56%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.